Clinical breast cancer最新文献

{"title":"Comprehensive analysis of HER2 Low Breast Cancer Response to Neoadjuvant Chemotherapy, a Retrospective Cohort Study.","authors":"Jie Lian, Ru Yao, Siyuan Pang, Xinyu Ren, Bo Pan, Yidong Zhou","doi":"10.1016/j.clbc.2025.03.013","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.03.013","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to identify the response and survival outcomes of HER2-low patients following neoadjuvant chemotherapy (NAC).</p><p><strong>Method: </strong>A retrospective cohort of patients who received NAC in the Department of Breast Surgery at Peking Union Medical College Hospital (PUMCH) from September 27, 2016, to January 23, 2024, was reviewed. Multivariate logistic regression and Cox proportional hazards models were used to identify factors associated with pathological complete response (pCR) and survival outcomes. The Kaplan-Meier method was applied to compare survival outcomes between HER2-zero and HER2-low patients.</p><p><strong>Result: </strong>Four hundred and twenty-one patients meeting the inclusion criteria. The pCR rate of HER2-zero patients was significantly higher than that of HER2-low patients after adjusting for confounders (OR = 2.83, 95% CI: 1.44-5.65, adjusted P = .003). HER2-low patients demonstrated the most stable status after NAC within the hormone receptor (HR)-positive subset (80.82%) and the most unstable status within the HR-negative subset (57.69%). HER2-zero status was associated with worse disease-free survival (DFS) (HR = 1.94, 95% CI: 1.13-3.32, adjusted P = .02), but not with overall survival (OS) (HR = 1.18, 95% CI: 0.59-2.37, P = .65). HER2-zero patients had significantly worse DFS than HER2-low patients in the entire cohort (P = .014) and the HR-positive subset (P < .001). pCR could serve as a surrogate endpoint of favorable survival outcomes for HER2-zero patients, but not for HER2-low patients.</p><p><strong>Conclusion: </strong>HER2-low patients might exhibit distinct characteristics compared with HER2-zero patients following NAC. Further multicenter, prospective studies are warranted to validate the conclusions of this exploratory research and assess whether HER2-low expression could serve as a new clinical subtype for evaluating NAC treatment outcomes.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143955031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study on Heparanase Promoting Breast Cancer Cell Proliferation and Inhibiting NK Cell Cytolytic Activity Via the PD-1/PD-L1 Pathway.","authors":"Jian Qiu, Zhongyi Shen, Guoqin Jiang, Qichao Ni","doi":"10.1016/j.clbc.2025.03.012","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.03.012","url":null,"abstract":"<p><strong>Objective: </strong>To explore the mechanism of action of heparanase (HPSE) in breast cancer (BC), particularly its impact on BC cell proliferation and natural killer (NK) cell cytolytic activity through the programmed cell death protein 1 (PD-1)/PD ligand 1 (PD-L1) pathway.</p><p><strong>Methods: </strong>HPSE expression levels were analyzed in BC cells. MDA-MB-231 cells, a widely used triple-negative BC model, were treated and assessed using RT-qPCR and Western blotting for gene and protein expression. CCK-8, Transwell assays, and flow cytometry were used to evaluate cell proliferation, migration, invasion, and apoptosis. NK cells isolated from healthy donors were treated with HPSE and co-cultured with BC cells to assess cytolytic activity through interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) release measurements. A nude mouse xenograft model was established to examine the in vivo effects of HPSE on tumor growth and NK cell function.</p><p><strong>Results: </strong>HPSE overexpression enhanced BC cell proliferation, migration, and invasion, while reducing apoptosis. It also upregulated PD-1 and PD-L1 expression, leading to impaired NK cell cytolytic activity and decreased secretion of TNF-α and IFN-γ. Inhibition of the PD-1/PD-L1 pathway partially reversed the pro-tumor effects of HPSE and restored NK cell cytolytic function. In vivo, HPSE overexpression promoted tumor growth and reduced NK cell activity within tumor tissues.</p><p><strong>Conclusion: </strong>These findings reveal HPSE as a key regulator of BC immune evasion, likely via modulation of the PD-1/PD-L1 axis. Targeting HPSE, particularly in combination with PD-1/PD-L1 inhibitors, may offer a novel therapeutic strategy for BC treatment.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of AKT Inhibitors for PIK3CA/AKT1/PTEN-Altered Advanced or Metastatic Breast Cancer: A Meta-Analysis of Randomized Clinical Trials","authors":"Francisco Cezar Aquino de Moraes ,&nbsp;Vitor Kendi Tsuchiya Sano ,&nbsp;Caroline R M Pereira ,&nbsp;Estella Aparecida de Laia ,&nbsp;Carlos Stecca ,&nbsp;Maria Cristina Figueroa Magalhães ,&nbsp;Paolo Tarantino","doi":"10.1016/j.clbc.2025.03.011","DOIUrl":"10.1016/j.clbc.2025.03.011","url":null,"abstract":"<div><h3>Purpose</h3><div>We aimed to answer the following question: How effective is the addition of AKT inhibitors to the treatment of advanced or metastatic breast cancer?</div></div><div><h3>Methods</h3><div>We searched PubMed, Embase and Cochrane for randomized controlled trials (RCTs) that investigated AKT inhibitors for advanced or metastatic BC. We computed hazard-ratios (HRs) for binary endpoints.</div></div><div><h3>Results</h3><div>A total of 5 RCTs were included in the meta-analysis, comprising 1,334 patients with BC. The use of AKT inhibitors demonstrated a significant improvement in OS (HR 0.70; 95% CI, 0.58-0.85; <em>P</em> &lt; .001) and PFS (HR 0.6797; 95% CI, 0.5499-0.8403; <em>P</em> &lt; .001) in the overall population. Within the PIK3CA/AKT1/PTEN-altered subgroup (n = 645), the OS rate also significantly favored AKT inhibitors over the control group (HR 0.62; 95% CI, 0.42-0.92; <em>P</em> = .019), as well as PFS (HR 0.5224; 95% CI, 0.3366-0.8105; <em>P</em> = .004).</div></div><div><h3>Conclusions</h3><div>Our findings suggest that the incorporation of AKT inhibitors holds promise for treating patients with advanced or metastatic PIK3CA/AKT1/PTEN-altered BC.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 5","pages":"Pages 391-400.e15"},"PeriodicalIF":2.9,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143976067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing Diagnostic Efficiency: A Radiomics Approach for Distinguishing Benign and Malignant Breast Lesions Using BI-RADS Features From Ultrasound Imaging.","authors":"Runqiu Cai, Man Wang, Yu Yan, Jingwu Ma, Xin Li, Xingbiao Chen, Sicong Huang, Xiaowei Cai, Linjing Shi, Yi Zhang, Yifei Qian","doi":"10.1016/j.clbc.2025.03.009","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.03.009","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is the leading cause of mortality from cancer in women worldwide. Ultrasound is commonly utilized to identify breast cancers but is dependent on operator experience. This study established a radiomics model aimed at enhancing diagnostic efficacy in distinguishing between benign and malignant breast lesions using ultrasound.</p><p><strong>Methods: </strong>A total of 316 patients were retrospectively included in this study. Two types of feature groups were extracted from ultrasound images: traditional radiomics features and customized features derived from BI-RADS (Breast Imaging Reporting & Data System) classification criteria. The radiomics features were categorized into 3 groups: (A) BI-RADS features, (B) radiomics features, and (C) a combination of both feature groups. Subsequently, SVM (Support Vector Machine), RF (Random Forest) and LR (Logistic Regression) algorithms were utilized to model and analyze based on the 3 feature groups. Finally, the model's performance was evaluated, and the SHAP method was employed to investigate the interpretability of the model.</p><p><strong>Results: </strong>In Group C, the SVM model demonstrated the best performance on the testing set, achieving an AUC and accuracy of approximately 0.91. The SHAP results revealed that the entropy and variance had the most significant impact on the output of the model (SVM for Group C).</p><p><strong>Conclusions: </strong>The SVM model constructed using BI-RADS features combined with radiomics feature demonstrated high diagnostic accuracy in distinguishing between benign and malignant breast lesions. This model may assist radiologists in differentiating malignant from benign breast lesions.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Tumor-Suppressive Role of miR-204-5p Through Targeting Ezrin in Breast Cancer: Experimental Evidence From Cell Lines and Clinical Samples","authors":"Tianfu Dong ,&nbsp;Honglei Zhou ,&nbsp;Jinhai Tang","doi":"10.1016/j.clbc.2025.02.013","DOIUrl":"10.1016/j.clbc.2025.02.013","url":null,"abstract":"<div><h3>Introduction</h3><div>Breast cancer (BC) remains one of the most prevalent malignancies and leading causes of cancer-related deaths among women worldwide. MicroRNA-204-5p (miR-204-5p) has been implicated in various cancers, where its downregulation is associated with adverse clinicopathological features and poor prognosis. Ezrin, a member of the ERM (Ezrin-Radixin-Moesin) family, links membrane proteins to the actin cytoskeleton and has been reported to play roles in tumor progression. However, the regulatory relationship between miR-204-5p and Ezrin in breast cancer remains unclear.</div></div><div><h3>Materials and Methods</h3><div>We conducted bioinformatics analyses using the TCGA BRCA dataset and GEO datasets GSE97811 and GSE144534 to evaluate the expression patterns of miR-204-5p and Ezrin. In vitro assays, including cell proliferation, migration, and invasion analyses, were performed to assess the functional effects of miR-204-5p in BC cells. Western blotting and luciferase reporter assays were used to confirm the regulatory relationship between miR-204-5p, Ezrin, and the AKT signaling pathway.</div></div><div><h3>Results</h3><div>miR-204-5p was significantly downregulated in breast cancer tissues and was associated with aggressive tumor characteristics and poor patient prognosis. Conversely, Ezrin was upregulated in BC tissues and identified as a direct target of miR-204-5p. Overexpression of miR-204-5p inhibited BC cell proliferation, migration, and invasion, while also reducing Ezrin expression. Mechanistic studies indicated that suppression of Ezrin by miR-204-5p led to downregulation of the AKT signaling pathway.</div></div><div><h3>Conclusion</h3><div>Our findings demonstrate that miR-204-5p functions as a tumor suppressor in breast cancer by targeting Ezrin and inhibiting the AKT pathway. This suggests a potential therapeutic role for miR-204-5p in the treatment of breast cancer.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 5","pages":"Pages e588-e596"},"PeriodicalIF":2.9,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143955630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is There Any Association Between Baseline Estrogen Concentration and Efficacy of Anastrozole in IBIS-II Prevention Trial?","authors":"Kadri Altundag","doi":"10.1016/j.clbc.2025.03.010","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.03.010","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Review of Current Literature and Real-World Outcomes With Neoadjuvant Chemotherapy in Hormone Receptor Positive, HER2 Negative Breast Cancer","authors":"Gregory Guzik ,&nbsp;Matthew Kurian ,&nbsp;Kanchi Patell ,&nbsp;Marcus Trybula ,&nbsp;Pingfu Fu ,&nbsp;Seunghee Margevicius ,&nbsp;Alberto Montero ,&nbsp;James Martin","doi":"10.1016/j.clbc.2025.03.008","DOIUrl":"10.1016/j.clbc.2025.03.008","url":null,"abstract":"<div><h3>Background</h3><div>Neoadjuvant chemotherapy has been used to downstage locally advanced ER+/HER2- breast cancer with low response rates. The optimal neoadjuvant regimen for this population is unknown.</div></div><div><h3>Patients and Methods</h3><div>Between 2017 and 2022, 192 patients (ages 28-78) with stage II/III ER+/Her2- breast cancer at our institution were evaluated. Patients were divided into 4 groups based on the neoadjuvant chemotherapy regimen used (AC-T, TC, TAC, or other). The responses were categorized as complete (ypT0/is ypN0), partial, no response, or progressive disease.</div></div><div><h3>Results</h3><div>The choice of neoadjuvant chemotherapy was not predictive of pCR (<em>P</em> = .3864), even among those with more advanced nodal disease. No significant difference was noted in OS or IDFS at 24 or 48 months between the AC-T and TC groups. In the AC-T group (<em>n</em> = 130), 9 patients had a CR (6.98%), while no patients in TC group had a CR. Those who were premenopausal were more likely to achieve pCR compared to those postmenopausal. Race significantly impacted IDFS.</div></div><div><h3>Conclusions</h3><div>In this single center study, we found no differences in IDFS or OS when comparing neoadjuvant TC to AC-T. The AC-T regimen group had a higher pCR rate of 6.98% compared to 0% in TC regimen group. Further exploration is needed to understand why non-white populations have inferior IDFS.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 5","pages":"Pages e666-e677"},"PeriodicalIF":2.9,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postmastectomy Radiation Therapy for Intermediate-Risk Breast Cancer Patients With 0-3 Positive Axillary Lymph Nodes: Emulating the SUPREMO Trial Using Real-World Data","authors":"Sarah E. Kulkarni ,&nbsp;Sagar A. Patel ,&nbsp;Chen Jiang ,&nbsp;Lara Schwieger ,&nbsp;Lauren M. Postlewait ,&nbsp;Cletus A. Arciero ,&nbsp;Theresa W. Gillespie ,&nbsp;Yuan Liu","doi":"10.1016/j.clbc.2025.03.007","DOIUrl":"10.1016/j.clbc.2025.03.007","url":null,"abstract":"<div><h3>Purpose</h3><div>To emulate the Selective Use of Postoperative Radiotherapy After Mastectomy (SUPREMO) phase III clinical trial using real-world data to assess the impact of postmastectomy radiation therapy (PMRT) on overall survival (OS) among patients with intermediate-risk breast cancer.</div></div><div><h3>Patients and Methods</h3><div>Using the National Cancer Database, women diagnosed between 2006 and 2013 with intermediate-risk breast cancer (defined as pT1-2N1; pT3N0; or pT2N0 and grade III or with lymphovascular invasion) and 0-3 positive axillary lymph nodes, who underwent total mastectomy, were identified as being in accordance with the SUPREMO trial protocol and included in this study. Multivariable logistic regression, Cox proportional hazards regression, and stabilized inverse probability of treatment weighting were used to explore the relationship between PMRT and OS. The effects of PMRT within subgroups were explored using multivariable interaction models.</div></div><div><h3>Results</h3><div>In total, 49335 patients were included in the study, with 6882 (13.9%) receiving PMRT. Patients with stage T3N0 cancer, 1-3 positive axillary lymph nodes, or positive surgical margins were more likely to receive PMRT. Overall, PMRT was associated with no significant improvement in OS (HR: 0.98, 95% CI, 0.92-1.04). However, improved survival was observed among women with stage T3N0 cancer who received PMRT (HR: 0.72, 95% CI, 0.58-0.89).</div></div><div><h3>Conclusion</h3><div>Although PMRT may not be associated with improved OS among all intermediate-risk breast cancer patients with 0-3 positive axillary lymph nodes, the subgroup of patients with stage T3N0 cancer seemed to benefit from PMRT. The study's retrospective nature introduces some uncertainty, but preliminary findings of the SUPREMO trial support these results.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 5","pages":"Pages e655-e665.e4"},"PeriodicalIF":2.9,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143787930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Forequarter Amputation for Breast Cancer. Systematic Review and Survival Analysis","authors":"Flávia Cardoso Franca ,&nbsp;Idam de Oliveira-Junior ,&nbsp;René Aloisio da Costa Vieira","doi":"10.1016/j.clbc.2025.03.005","DOIUrl":"10.1016/j.clbc.2025.03.005","url":null,"abstract":"<div><h3>Introduction</h3><div>Forequarter amputation (FA) or Interscapulothoracic disarticulation is indicated in patients with invasive breast carcinoma (BC) in selected cases: primary resection of a locally advanced or recurrent tumor, Stewart &amp; Treves syndrome (STS), or sarcoma secondary to radiation due to breast cancer (radiation-induced sarcoma, RIS). However, no studies have robustly evaluated the indications, results, complications, recurrence and overall survival in the context of FA in patients with BC.</div></div><div><h3>Material and Methods</h3><div>We performed a systematic review of 8 databases according to the PICOS and PRISMA methodology through December 31, 2022. Descriptive statistics are presented, and Kaplan‒Meier survival curves were generated and compared with the log-rank method.</div></div><div><h3>Results</h3><div>We identified 54 articles and collected data from 100 patients. The intention of FA was curative for 48 patients (57.1%) and palliative in 32 (38.1%). The procedure was performed due to STS (35%), upper limb dysfunction (18%), lymphedema (10%), recurrent axillary tumors (10%) and RIS (9%). Complications were low. The survival rates at 12, 24, 36, and 60 months were 65.6%, 42.8%, 36.4%, and 32.4%, respectively. The main factors associated with survival were tumor's condition (<em>P</em> = .05) and surgical intent (<em>P</em> &lt; .001; multivariate analysis).</div></div><div><h3>Conclusion</h3><div>FA has few complications and attenuates symptoms in patients treated with both curative and palliative intent. Surgery is justified in select cases, such as locally advanced tumors, infiltration of axillary structures, upper limb lymphedema with loss of function, and STS and RIS, and often represents the best chance for local disease control and improvement in quality of life.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 5","pages":"Pages e645-e654.e9"},"PeriodicalIF":2.9,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Harnessing Artificial Intelligence for Precision Diagnosis and Treatment of Triple Negative Breast Cancer","authors":"Md Sadique Hussain ,&nbsp;Prasanna Srinivasan Ramalingam ,&nbsp;Gayathri Chellasamy ,&nbsp;Kyusik Yun ,&nbsp;Ajay Singh Bisht ,&nbsp;Gaurav Gupta","doi":"10.1016/j.clbc.2025.03.006","DOIUrl":"10.1016/j.clbc.2025.03.006","url":null,"abstract":"<div><div>Triple-Negative Breast Cancer (TNBC) is a highly aggressive subtype of breast cancer (BC) characterized by the absence of estrogen, progesterone, and HER2 receptors, resulting in limited therapeutic options. This article critically examines the role of Artificial Intelligence (AI) in enhancing the diagnosis and treatment of TNBC treatment. We begin by discussing the incidence of TNBC and the fundamentals of precision medicine, emphasizing the need for innovative diagnostic and therapeutic approaches. Current diagnostic methods, including conventional imaging techniques and histopathological assessments, exhibit limitations such as delayed diagnosis and interpretative discrepancies. This article highlights AI-driven advancements in image analysis, biomarker discovery, and the integration of multi-omics data, leading to enhanced precision and efficiency in diagnosis and treatment. In treatment, AI facilitates personalized therapeutic strategies, accelerates drug discovery, and enables real-time monitoring of patient responses. However, challenges persist, including issues related to data quality, model interpretability, and the societal impact of AI implementation. In the conclusion, we discuss the future prospects of integrating AI into clinical practice and emphasize the importance of multidisciplinary collaboration. This review aims to outline key trends and provide recommendations for utilizing AI to improve TNBC management outcomes, while highlighting the need for further research.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 5","pages":"Pages 406-421"},"PeriodicalIF":2.9,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}